Effectiveness of Mindfulness-Based Cognitive Therapy With Follow-Up Sessions for Pharmacotherapy-Refractory Anxiety Disorders: Protocol for a Feasibility Randomized Controlled Trial (Preprint)
Authors:
- Mitsuhiro SadoMSMitsuhiro Sado
- Akira NinomiyaANAkira Ninomiya
- Maki NagaokaMNMaki Nagaoka
- Akihiro KorekiAKAkihiro Koreki
- Naho GotoNGNaho Goto
- Yohei SasakiYSYohei Sasaki
- Chie TakamoriCTChie Takamori
- Teppei KosugiTKTeppei Kosugi
- Masashi YamadaMYMasashi Yamada
- Sunre ParkSPSunre Park
- Yasunori SatoYSYasunori Sato
- Daisuke FujisawaDFDaisuke Fujisawa
Preprint
- 22 September 2021
- preprint
- Published by JMIR Publications Inc. in JMIR Preprints
Abstract
BACKGROUND Augmented mindfulness-based cognitive therapy (MBCT) with treatment as usual (mainly pharmacotherapy) is reported to be effective after treatment for anxiety disorders. However, whether its effectiveness persists in the long term is unclear. OBJECTIVE This study aims to examine the feasibility, acceptability, and effectiveness of a follow-up program by conducting a feasibility randomized controlled trial (RCT) that compares augmented MBCT with follow-up sessions and that without follow-up sessions in preparation for a definitive RCT. METHODS The study involves an 8-week MBCT with a 10-month follow-up. Patients aged 20 to 65 years who meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for panic disorder, agoraphobia, or social anxiety disorder, which is not remitted with usual treatment for at least 4 weeks, will be included in the study and randomly allocated to receive augmented MBCT with follow-up sessions or augmented MBCT without follow-up sessions. For this feasibility RCT, the primary outcomes are (1) study inclusion rate, (2) dropout rate, (3) attendance rate, and (4) mean and standard deviation of several clinical measures at 8 weeks and 5, 8, and 12 months. RESULTS We started recruiting participants in January 2020, and 43 participants have been enrolled up to January 2021. The study is ongoing, and data collection will be completed by May 2022. CONCLUSIONS This study is novel in terms of its design, which compares augmented MBCT with and without follow-up sessions. The limitations of the trial are as follows: (1) mixed participants in terms of the delivery mode of the intervention, and (2) lack of a pharmacotherapy-alone arm. Owing to its novelty and significance, this study will provide fruitful knowledge for future definitive RCTs. CLINICALTRIAL UMIN Clinical Trials Registry UMIN000038626; https://tinyurl.com/2p9dtxzh INTERNATIONAL REGISTERED REPORT DERR1-10.2196/33776Keywords
All Related Versions
- Published version: JMIR Research Protocols, 11 (1), e33776.
This publication has 61 references indexed in Scilit:
- Cost of anxiety disorders in Japan in 2008: a prevalence-based approachBMC Psychiatry, 2013
- Reliability and Validity of Japanese Versions of the Flourishing Scale and the Scale of Positive and Negative ExperienceSocial Indicators Research, 2013
- The Multidimensional Assessment of Interoceptive Awareness (MAIA)PLOS ONE, 2012
- The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiencyJournal of Clinical Epidemiology, 2012
- Quality of and Patient Satisfaction With Primary Health Care for Anxiety DisordersThe Journal of Clinical Psychiatry, 2011
- A Japanese version of the Perceived Stress Scale: cross-cultural translation and equivalence assessmentBMC Psychiatry, 2008
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- Prevalence, Severity, and Unmet Need for Treatment of Mental Disorders in the World Health Organization World Mental Health SurveysJAMA, 2004
- Validating the SF-36 health survey questionnaire: new outcome measure for primary care.BMJ, 1992